Molecular structure of Quetiapine Fumarate, CAS Number: 111974-72-2
Quetiapine Fumarate (CAS 111974-72-2)
See product citations (1)
Alternate Names:
Quetiapine hemifumarate salt; Seroquel
Application:
Quetiapine Fumarate is an inhibitor of D2DR and SR-2A
CAS Number:
111974-72-2
Molecular Weight:
883.10
Molecular Formula:
C46H54N6O8S2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Quetiapine fumarate is an inhibitor of D2DR and SR-2A. Quetiapine Fumarate has been the subject of in vitro studies exploring its impact on biochemical processes, including its influence on neurotransmitters and its ability to regulate various physiological functions. The research has revealed that it exhibits a notable affinity for dopamine and serotonin receptors, showcasing its effectiveness in modulating physiological processes like cell growth, differentiation, and apoptosis.
Quetiapine Fumarate (CAS 111974-72-2) References
- Atypical antipsychotic effects of quetiapine fumarate in animal models. | Guan, HJ., et al. 2000. Acta Pharmacol Sin. 21: 205-10. PMID: 11324416
- Quetiapine-induced peripheral edema. | Roy, K., et al. 2009. Gen Hosp Psychiatry. 31: 194-5. PMID: 19269545
- Extended release quetiapine fumarate and pregnancy. | Tényi, T., et al. 2013. Neuropsychopharmacol Hung. 15: 49-50. PMID: 23542759
- Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. | Zhornitsky, S., et al. 2013. CNS Neurosci Ther. 19: 737-44. PMID: 23870612
- Quetiapine extended release for the treatment of bipolar disorder. | Samalin, L., et al. 2014. Expert Rev Neurother. 14: 987-1005. PMID: 25096854
- Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability. | Narala, A. and Veerabrahma, K. 2013. J Pharm (Cairo). 2013: 265741. PMID: 26555970
- Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. | Akhlaq, M., et al. 2018. Drug Deliv. 25: 916-927. PMID: 29649903
- Degradation studies of quetiapine fumarate by liquid chromatography-diode array detection and tandem mass spectrometry methods. | de Diego, M., et al. 2019. Biomed Chromatogr. 33: e4655. PMID: 31322744
- Quetiapine Fumarate Extended-release Tablet Formulation Design Using Artificial Neural Networks. | Özçelik, E., et al. 2017. Turk J Pharm Sci. 14: 213-221. PMID: 32454616
- Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment. | Agarwal, S., et al. 2021. Curr Drug Deliv. 18: 184-198. PMID: 32723273
- Low-Dose Quetiapine Fumarate (50 mg) for Obsessive-Compulsive Disorder Patients With Comorbid Bipolar Depression. | Poyurovsky, M. and Weizman, A. Clin Neuropharmacol. 44: 196-197. PMID: 34456228
- Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane. | Bhupathyraaj, M., et al. 2022. Polymers (Basel). 14: PMID: 35631867
- Quantification of quetiapine fumarate based on electrochemical analysis by reduced graphene oxide modified nano-silica functionalized with polydopamine and gold nanostars: A novel pharmaceutical analysis strategy. | Ghaseminasab, K., et al. 2022. J Mol Recognit. 35: e2977. PMID: 35642074
Inhibitor of:
D2DR, NPAS3, and SR-2A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Quetiapine Fumarate, 1 g | sc-219681 | 1 g | $122.00 | |||
Quetiapine Fumarate, 5 g | sc-219681A | 5 g | $495.00 |